Christopher Wiegand M.D. reports about a study that investigated the safety, tolerability, and clinical effects of psilocybin, a potent serotonin agonist, in nine patients with Obsessive Compulsive Disorder (OCD). Subjects participated in up to 4 single-dose exposures to psilocybin, separated by at least 1 week, in doses ranging from sub-hallucinogenic to frankly hallucinogenic. Sessions lasted 8-hours in a controlled clinical environment, followed by overnight hospitalization. The Yale-Brown Obsessive Compulsive Scale (YBOCS) was administered at speciﬁc intervals, and vital signs monitored. One subject experienced transient hypertension without relation to anxiety or somatic symptoms, but no other signiﬁcant adverse effects were observed. Marked decreases in OCD symptoms were observed in all subjects during 1 or more of the testing sessions (23%- 100% decrease in YBOCS score) and generally lasted at least 24 hours. Repeated-measures analysis of variance for all YBOCS values revealed a signiﬁcant main effect of time, but no effect of dose. In a controlled clinical environment, psilocybin was safely used in subjects with OCD and was associated with acute reductions in core OCD symptoms in several subjects.studying psychoactive compounds. Is this methodology appropriate and sufﬁcient to study psychedelic medicines? The analysis of the above questions is separated into ﬁve themes: 1) A discussion of the evolution of the therapeutic paradigms used in the studies. 2) An analysis of the political and interpersonal contexts affecting the research. 3) A description of the major studies conducted at Spring Grove State Hospital and the MPRC highlighting the methodological issues. 4) A survey of the non-drug therapies that evolved from the psychedelic research. 5) The current status of research and possible future directions for psychedelic research.
This video was produced by Teal Sievers with Living Dream Films